Renal Cell Carcinoma: A Cancer-testis Antigen Poor Malignancy

Authors

  • Sepideh Faramarzi Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Soudeh Ghafouri-Fard

Keywords:

Renal cell carcinoma- cancer-testis antigen- biomarker- immunotherapy

Abstract

Renal cell carcinoma (RCC) is a relatively frequent cancer with increasing incidence in some regions. There is a need for early diagnosis of this cancer as a significant number of patients develop metastasis in their clinical course. Cancer-testis antigens (CTAs) are a group of tumor associated antigens whose expression has been assessed in a wide range of malignancies. CTAs are also considered as immunotherapy targets. Considering the relative responsiveness of RCC patients to immunotherapy, expression analysis of CTAs in RCC is of clinical importance. However, data regarding expression of CTAs in RCC is scarce except for a few numbers of CTAs including NY-ESO-1. The expression pattern of CTAs in RCC samples and cell lines is reviewed in this manuscript.

Downloads

Published

2017-09-25

Issue

Vol. 2 No. 3 (2017)

Section

Research Articles/ Original Work

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).